scispace - formally typeset
A

Armando Tripodi

Researcher at University of Milan

Publications -  301
Citations -  17418

Armando Tripodi is an academic researcher from University of Milan. The author has contributed to research in topics: Prothrombin time & Thrombomodulin. The author has an hindex of 60, co-authored 278 publications receiving 14939 citations. Previous affiliations of Armando Tripodi include Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico & University of Bari.

Papers
More filters
Journal ArticleDOI

Update of the guidelines for lupus anticoagulant detection

TL;DR: Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT and the interpretation of the results in general and in particular situations is reported.
Journal ArticleDOI

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.

TL;DR: The severe inflammatory state secondary to COVID‐19 leads to a severe derangement of hemostasis that has been recently described as a state of disseminated intravascular coagulation (DIC) and consumption coagulopathy, defined as decreased platelet count, increased fibrin(ogen) degradation products such as D‐dimer, as well as low fibrInogen.
Journal ArticleDOI

The Coagulopathy of Chronic Liver Disease

TL;DR: In this paper, the authors consider the evidence regarding the balance in the hemostatic system (involving coagulation, platelets, and fibrinolysis).
Journal ArticleDOI

Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.

TL;DR: In this paper, the authors used a thrombin generation test to investigate the coagulation function in patients with cirrhosis, and they found that the reduction of pro-coagulant factors in patients had little impact on the reduction in anticoagulants.
Journal ArticleDOI

An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis.

TL;DR: The hypercoagulability of plasma from patients with cirrhosis appears to result from increased levels of factor VIII and decreased levels of protein C-typical features of patients with Cirrhosis, which might explain the risk for venous thromboembolism in patients with chronic liver disease.